BACKGROUND: In Bolivia, in 2008, the under-five mortality rate is 54 per 1000 live births. Diarrhea causes 15% of these deaths, and 40% of pediatric diarrhea-related hospitalizations are caused by rotavirus illness (RI). Rotavirus vaccination (RV), subsidized by international donors, is expected to reduce morbidity, mortality, and economic burden to the Bolivian state. Estimates of illness and economic burden of RI and their reduction by RV are essential to the Bolivian state's policies on RV program financing. The goal of this report is to estimate the economic burden of RI and the cost-effectiveness of the RV program. METHODS: To assess treatment costs incurred by the healthcare system, we abstracted medical records from 287 inpatients and 6751 outpatients with acute diarrhea between 2005 and 2006 at 5 sentinel hospitals in 4 geographic regions. RI prevalence rates were estimated from 4 years of national hospital surveillance. We used a decision-analytic model to assess the potential cost-effectiveness of universal RV in Bolivia. RESULTS: Our model estimates that, in a 5-year birth cohort, Bolivia will incur over US$3 million in direct medical costs due to RI. RV reduces, by at least 60%, outpatient visits, hospitalizations, deaths, and total direct medical costs associated with rotavirus diarrhea. Further, RV was cost-savings below a price of US$3.81 per dose and cost-effective below a price of US$194.10 per dose. Diarrheal mortality and hospitalization inputs were the most important drivers of rotavirus vaccine cost-effectiveness. DISCUSSION: Our data will guide Bolivia's funding allocation for RV as international subsidies change.
BACKGROUND: In Bolivia, in 2008, the under-five mortality rate is 54 per 1000 live births. Diarrhea causes 15% of these deaths, and 40% of pediatric diarrhea-related hospitalizations are caused by rotavirus illness (RI). Rotavirus vaccination (RV), subsidized by international donors, is expected to reduce morbidity, mortality, and economic burden to the Bolivian state. Estimates of illness and economic burden of RI and their reduction by RV are essential to the Bolivian state's policies on RV program financing. The goal of this report is to estimate the economic burden of RI and the cost-effectiveness of the RV program. METHODS: To assess treatment costs incurred by the healthcare system, we abstracted medical records from 287 inpatients and 6751 outpatients with acute diarrhea between 2005 and 2006 at 5 sentinel hospitals in 4 geographic regions. RI prevalence rates were estimated from 4 years of national hospital surveillance. We used a decision-analytic model to assess the potential cost-effectiveness of universal RV in Bolivia. RESULTS: Our model estimates that, in a 5-year birth cohort, Bolivia will incur over US$3 million in direct medical costs due to RI. RV reduces, by at least 60%, outpatient visits, hospitalizations, deaths, and total direct medical costs associated with rotavirus diarrhea. Further, RV was cost-savings below a price of US$3.81 per dose and cost-effective below a price of US$194.10 per dose. Diarrheal mortality and hospitalization inputs were the most important drivers of rotavirus vaccine cost-effectiveness. DISCUSSION: Our data will guide Bolivia's funding allocation for RV as international subsidies change.
Authors: D Panatto; D Amicizia; F Ansaldi; A Marocco; F Marchetti; F Bamfi; R Giacchino; A Tacchella; S Del Buono; R Gasparini Journal: Vaccine Date: 2009-02-05 Impact factor: 3.641
Authors: Andrea S Mendelsohn; Jaya Ruth Asirvatham; D Mkaya Mwamburi; T V Sowmynarayanan; Vandana Malik; Jayaprakash Muliyil; Gagandeep Kang Journal: Trop Med Int Health Date: 2008-05-06 Impact factor: 2.622
Authors: Joke Bilcke; Pierre Van Damme; Frank De Smet; Germaine Hanquet; Marc Van Ranst; Philippe Beutels Journal: Eur J Pediatr Date: 2008-03-04 Impact factor: 3.183
Authors: Christine Marie George; Jamie Perin; Karen J Neiswender de Calani; W Ray Norman; Henry Perry; Thomas P Davis; Erik D Lindquist Journal: Am J Trop Med Hyg Date: 2014-10-13 Impact factor: 2.345
Authors: A D Steele; J C Victor; M E Carey; J E Tate; D E Atherly; C Pecenka; Z Diaz; U D Parashar; C D Kirkwood Journal: Hum Vaccin Immunother Date: 2019-02-08 Impact factor: 3.452
Authors: Rachel M Burke; Paulina A Rebolledo; Sally R Embrey; Laura Danielle Wagner; Carter L Cowden; Fiona M Kelly; Emily R Smith; Volga Iñiguez; Juan S Leon Journal: BMC Public Health Date: 2013-08-02 Impact factor: 3.295
Authors: Rachel M Burke; Emily R Smith; Rebecca Moritz Dahl; Paulina A Rebolledo; Maria del Carmen Calderón; Beatriz Cañipa; Edgar Chavez; Rolando Pinto; Luis Tamayo; Carlos Terán; Angel Veizaga; Remy Zumaran; Volga Iñiguez; Juan S Leon Journal: BMC Public Health Date: 2014-06-24 Impact factor: 3.295